US Patent 8,618,135: Lomitapide Dose-Escalation Claims, Patent Scope, and Generic Entry Risk

US Patent 8,618,135 protects a stepwise dose-escalation regimen for lomitapide, the microsomal triglyceride transfer protein inhibitor marketed as Juxtapid in the United States. The patent does not broadly claim every use of lomitapide. Its principal value is narrower: it covers staged increases in daily lomitapide dose for treating hyperlipidemia or hypercholesterolemia, including severe hypercholesterolemia and homozygous familial hypercholesterolemia.

The core regimen requires at least three increasing dose levels, generally administered over sequential one- to five-week periods. Dependent claims add oral administration, lipid-reduction thresholds, fourth- and fifth-stage escalation, and narrower two- to four-week treatment intervals. The claims closely track the FDA-approved titration pattern of 5 mg, 10 mg, 20 mg, 40 mg, and 60 mg once daily.

What drug and regimen does US Patent 8,618,135 cover?

The claimed MTP inhibitor is lomitapide, also known as BMS-201038. Lomitapide is a small-molecule inhibitor of microsomal triglyceride transfer protein, or MTP. It reduces hepatic production of very-low-density lipoprotein and intestinal production of chylomicrons, lowering LDL cholesterol and other atherogenic lipoproteins.

The patent is directed to treatment methods rather than a broad composition-of-matter claim. Its commercial relevance comes from the relationship between the patented regimen and the approved Juxtapid dosing schedule.

Item	Patent-relevant information
Active ingredient	Lomitapide
Mechanism	Microsomal triglyceride transfer protein inhibition
Brand	Juxtapid
US sponsor at approval	Aegerion Pharmaceuticals
FDA application	NDA 203858
Initial FDA approval	December 21, 2012
Approved indication	Homozygous familial hypercholesterolemia
Dosage form	Oral capsule
Label titration	5 mg daily, then 10 mg, 20 mg, 40 mg, and up to 60 mg daily
Patent subject matter	Stepwise dose escalation for hyperlipidemia or hypercholesterolemia
Patent number	US 8,618,135
Patent type	Utility patent claiming methods of treatment

The patent claims use a structural definition rather than the name “lomitapide.” That definition covers lomitapide, pharmaceutically acceptable salts, and the piperidine N-oxide form. A generic product using the same active compound would therefore remain within the chemical limitation if it practices the claimed dosing method.

What are the independent claims of US 8,618,135?

Claims 1, 9, and 10 are the principal independent claims. They share four required elements:

Treatment of hyperlipidemia or hypercholesterolemia.
Administration of an effective amount of the specified MTP inhibitor.
At least three stepwise, increasing dose levels.
The specified daily-dose ranges and treatment durations.

Claim 1

Claim 1 requires:

A first daily dose from about 2 mg to about 13 mg.
A second daily dose from about 5 mg to about 30 mg.
A third daily dose from about 10 mg to about 50 mg.
Each dose level administered for about one to five weeks.
Lomitapide, an acceptable salt, or the piperidine N-oxide.

The claim does not require the exact commercial sequence of 5 mg, 10 mg, and 20 mg. It uses overlapping numerical ranges. A regimen of 5 mg, 10 mg, and 20 mg falls within all three ranges.

Claim 9

Claim 9 narrows the duration requirements:

First dose: 2 mg to 13 mg daily for about two weeks.
Second dose: 5 mg to 30 mg daily for about two to four weeks.
Third dose: 10 mg to 50 mg daily for about two to four weeks.

This claim is particularly aligned with standard label-based titration because the commercial schedule generally begins at 5 mg daily and increases at intervals of at least two weeks.

Claim 10

Claim 10 uses a different duration structure:

First dose: 2 mg to 13 mg daily for about one to 12 weeks.
Second dose: 5 mg to 30 mg daily for about four weeks.
Third dose: 10 mg to 50 mg daily for about four weeks.

This claim can capture slower titration schedules that maintain the second and third levels for four weeks.

How broad are the dose ranges in Patent 8,618,135?

The dose ranges are broad enough to cover most clinically recognizable lomitapide escalation schedules, but the claims impose a meaningful sequence requirement.

Dose stage	Claimed range	Commercially relevant examples
First	About 2 to 13 mg/day	5 mg/day
Second	About 5 to 30 mg/day	10 mg/day
Third	About 10 to 50 mg/day	20 mg/day or 40 mg/day
Fourth	About 20 to 60 mg/day	40 mg/day or 60 mg/day
Fifth	About 30 to 75 mg/day	60 mg/day

The ranges overlap. That overlap creates multiple potentially infringing sequences. For example:

5 mg, 10 mg, 20 mg
5 mg, 10 mg, 40 mg
5 mg, 20 mg, 40 mg
10 mg, 20 mg, 40 mg
5 mg, 10 mg, 20 mg, 40 mg
5 mg, 10 mg, 20 mg, 40 mg, 60 mg

The claims do not require use of the maximum 60 mg dose. A three-stage regimen ending at 20 mg or 40 mg can satisfy the independent claims if the timing and other limitations are met.

What do the dependent claims add?

Claims 2 through 4: Disease and pharmacodynamic limitations

Claim 2 limits the treated condition to severe hypercholesterolemia.

Claims 3 and 4 require specified lipid or apolipoprotein reductions compared with control levels. Claim 3 uses a reduction of at least 15%; claim 4 uses at least 25%.

The covered biomarkers include:

Total cholesterol
LDL cholesterol
Fasting triglycerides
VLDL
Lipoprotein(a)
Apolipoproteins A-I, A-II, B, and E

These claims add potential enforcement value where clinical data establish the required reduction. They also create proof issues because the comparison must be made against “control levels,” and the patent language may require a defined baseline or control population.

Claim 5: Oral administration

Claim 5 requires oral administration. This limitation matches the approved capsule product and is commercially important because a generic oral lomitapide product would likely practice the claim when marketed with the patented titration schedule.

Claims 6 through 8: Four- and five-stage regimens

Claim 6 adds a fourth dose level.

Claim 7 adds both a fourth and fifth dose level.

Claim 8 specifies:

Fourth dose: about 20 to 60 mg/day.
Fifth dose: about 30 to 75 mg/day.

The FDA-approved Juxtapid schedule of 5 mg, 10 mg, 20 mg, 40 mg, and 60 mg daily falls within the five-stage structure of claims 7 and 8.

Does the FDA-approved Juxtapid regimen fall within the patent claims?

Yes. The labeled Juxtapid regimen is closely aligned with the claimed subject matter.

The FDA label directs treatment to begin at 5 mg once daily and increase to 10 mg after at least two weeks. Later increases to 20 mg, 40 mg, and 60 mg occur at intervals of at least four weeks, subject to tolerability and clinical response. That sequence maps as follows:

FDA-labeled step	Patent claim coverage
5 mg/day	First dose range
10 mg/day	Second dose range
20 mg/day	Third dose range
40 mg/day	Fourth dose range
60 mg/day	Fifth dose range
Oral capsule administration	Claim 5
Treatment of HoFH	Claim 2 and underlying indication

The overlap is strongest for claims 7 and 8, which cover a five-stage escalation ending at 60 mg/day. Claims 1 and 9 can also cover the early three-stage sequence.

When does US Patent 8,618,135 expire?

The patent’s base twenty-year term is tied to its earliest effective nonprovisional or international filing date, not simply its issue date. Based on the patent family priority structure, the nominal term is expected to run into late 2028, subject to any applicable patent-term adjustment.

The commercially relevant expiration analysis is:

Exclusivity component	Expected end point
US 8,618,135 base patent term	Approximately December 2028
Patent-term adjustment	Must be added if awarded by the USPTO
FDA orphan-drug exclusivity	Separate seven-year period from the 2012 approval
Pediatric exclusivity	No extension should be assumed without an applicable FDA determination
Regulatory exclusivity effect	Does not replace patent expiration analysis

Patent term must be confirmed against the USPTO maintenance and term-adjustment records and the current FDA Orange Book entry. Patent expiration is distinct from FDA regulatory exclusivity. The 2012 orphan-drug exclusivity period for Juxtapid would have expired before the expected end of the patent term.[1][2]

What is the Orange Book status of Juxtapid and lomitapide?

Juxtapid was approved under NDA 203858 for adults with homozygous familial hypercholesterolemia. The product received accelerated approval based on LDL-cholesterol reduction, with continued approval dependent on clinical benefit under the applicable regulatory framework.[2]

The Orange Book is the controlling FDA source for listed patents and approved-use information. For a generic applicant, the practical question is whether US 8,618,135 is listed against the relevant NDA and whether the proposed ANDA label would practice the patented dosing method.

A method-of-use patent creates several possible ANDA outcomes:

Paragraph III certification if the applicant accepts a later launch date.
Paragraph IV certification if the applicant asserts invalidity, unenforceability, or noninfringement.
Section viii statement if the applicant can carve out the patented method from its labeling.
Commercial risk if the FDA-approved generic label still instructs the staged dosing sequence.

Because the patented regimen is closely associated with the only approved dosing schedule, a clean section viii carve-out may be difficult if the proposed generic label must describe dose escalation for safe use.

How strong is the patent estate for lomitapide?

US 8,618,135 is strongest as a regimen patent. It is not equivalent to a composition-of-matter patent and should not be treated as blocking every possible lomitapide sale independently of the claimed method.

Strengths

The claims cover the standard clinical titration sequence.
The dose ranges are broad and overlap at each stage.
The claims cover three-, four-, and five-stage regimens.
Oral administration is expressly claimed.
The claims reach treatment of hypercholesterolemia and severe hypercholesterolemia.
The commercial label substantially follows the claimed sequence.

Limitations

A plaintiff must prove actual practice of the dose-escalation limitations.
The claims require increasing dose levels, not merely administration of a fixed dose.
Duration requirements may create noninfringement positions.
A generic label may attempt to omit or modify the patented titration instructions.
The biomarker claims require proof of the specified reductions against an appropriate control.
The patent does not necessarily cover every formulation, manufacturing process, or use of lomitapide.

The patent is therefore commercially meaningful but more vulnerable to design-around arguments than a composition patent. A generic applicant could seek to avoid infringement by using a fixed-dose label, omitting the patented escalation schedule, or relying on physician-directed dosing language. The viability of those strategies depends on FDA labeling requirements and the actual proposed ANDA label.

What other patent categories affect generic lomitapide entry?

A complete lomitapide freedom-to-operate review should separate the estate into five categories.

Composition patents

Composition patents cover the chemical compound, salts, stereoisomers, metabolites, or related MTP inhibitors. Their expiration dates and validity determine whether a generic can manufacture or sell lomitapide at all.

Method-of-use patents

US 8,618,135 is principally in this category. Other use patents may address HoFH, LDL reduction, triglyceride reduction, or combination treatment.

Formulation patents

Formulation patents may cover capsule composition, excipients, particle size, dissolution, bioavailability, or food-effect management. These patents can remain relevant after a composition patent expires if the generic uses the protected formulation.

Manufacturing patents

Manufacturing patents may cover synthetic intermediates, chiral resolution, purification, crystallization, salt formation, or impurity control. They create process risk even where the final active ingredient is no longer composition-patent protected.

Regulatory and labeling protections

The FDA label, REMS obligations, contraindications, and food-administration instructions can constrain a generic applicant’s ability to omit the patented titration sequence. Juxtapid has significant safety-management requirements because of hepatotoxicity and embryo-fetal toxicity concerns.[2]

Which companies are challenging Juxtapid exclusivity?

The claim text alone does not establish the identity or status of Paragraph IV challengers, ANDA litigation, or settlement agreements. Those issues must be determined from current FDA Orange Book records, FDA Paragraph IV notices, PACER filings, and the patent’s prosecution and litigation history.

For transaction or launch analysis, the relevant diligence points are:

Issue	Business effect
Paragraph IV filing	May trigger patent litigation and a 30-month FDA stay
Section viii carve-out	May permit approval but limit the generic label
Settlement agreement	May establish a negotiated launch date or supply arrangement
ANDA approval	Does not itself resolve patent infringement liability
Patent expiration	Controls the outer boundary for the claimed regimen
Orphan exclusivity	May restrict approval for the same indication during its term

A generic launch before late 2028 would face the greatest risk if the ANDA label instructs 5 mg-to-10 mg-to-20 mg-to-40 mg-to-60 mg titration.

What generic launch scenarios exist for lomitapide?

Scenario 1: Launch after patent expiration

This is the lowest litigation-risk scenario. The generic may use the full dose-escalation instructions after the patent term ends, subject to any other unexpired patents.

Scenario 2: Paragraph IV challenge

The applicant may argue that the claims are invalid or not infringed. Potential arguments could focus on:

Obviousness of dose escalation from prior MTP inhibitor studies.
Lack of written description or enablement for the full dose ranges.
Indefiniteness of “about,” “effective amount,” or “control levels.”
Noninfringement based on a label that omits the claimed regimen.
Lack of induced infringement where the label does not instruct the patented method.

Scenario 3: Section viii labeling carve-out

The applicant may seek to omit the patented use from its label. This approach is less attractive where dose escalation is necessary for the approved product’s safe and effective use.

Scenario 4: Alternative titration

A generic could pursue a different dosing schedule, such as a fixed dose or a non-overlapping duration structure. That strategy must remain medically supportable and acceptable to FDA reviewers.

How does US 8,618,135 compare with a composition patent?

Feature	US 8,618,135	Composition patent
Protected subject matter	Treatment regimen	Chemical compound or salt
Infringement focus	Product labeling and use	Making, using, selling, or importing compound
Design-around potential	Moderate to high	Low if valid and unexpired
Dependence on physician behavior	Higher	Lower
Relevance to ANDA label	Very high	High
Typical vulnerability	Noninfringement and obviousness	Validity, novelty, written description
Commercial blocking power	Narrower	Broader

The patent has high relevance to label-based generic litigation but does not independently establish a monopoly over all lomitapide products.

Key Takeaways

US 8,618,135 is a lomitapide method-of-treatment patent.
Its principal protection is a staged dose-escalation regimen for hyperlipidemia or hypercholesterolemia.
The claimed ranges cover the commercial Juxtapid sequence of 5 mg, 10 mg, 20 mg, 40 mg, and 60 mg daily.
Claims 7 and 8 are particularly important because they cover four- and five-stage escalation.
The patent’s base term is expected to run into late 2028, subject to USPTO patent-term adjustment.
The patent is stronger against a generic label that expressly reproduces the FDA titration schedule.
It is weaker than a composition patent because a generic may pursue label carve-outs, fixed-dose instructions, or alternative titration.
Orange Book listings, Paragraph IV certifications, ANDA litigation, and settlement terms must be assessed separately from the claim language.
Lomitapide is a small molecule, so biosimilar analysis is not applicable. The relevant competitive threat is generic, not biosimilar, entry.

FAQs

Is US 8,618,135 a patent on the lomitapide molecule itself?

No. The patent principally claims methods of treating hyperlipidemia using lomitapide through staged dose escalation. Composition patents must be analyzed separately.

Does a 5 mg-to-10 mg-to-20 mg regimen infringe the patent?

That sequence falls within the numerical dose ranges of the principal claims. Infringement also depends on the treatment durations, indication, compound identity, and other claim limitations.

Does a generic need to use 60 mg lomitapide to infringe?

No. The independent claims can be practiced with three escalating dose levels. The five-stage claims reach a 60 mg final dose, but use of the maximum dose is not required for every claim.

Are biosimilars relevant to Juxtapid?

No. Lomitapide is a chemically synthesized small molecule. The relevant competitors are ANDA-based generic manufacturers.

Can a generic avoid the patent by omitting dose-escalation instructions?

Possibly, but the strategy depends on whether FDA permits the proposed labeling and whether physicians are likely to use the generic for the patented method. Label design, induced infringement, and FDA approval requirements would be central issues.

References

United States Patent and Trademark Office. (2013). U.S. Patent No. 8,618,135, Methods for treating hyperlipidemia.
U.S. Food and Drug Administration. (2024). Juxtapid (lomitapide) prescribing information.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (2012). FDA approves Juxtapid to treat patients with homozygous familial hypercholesterolemia.
U.S. Food and Drug Administration. (2024). Approved drug product and patent listing requirements under the Hatch-Waxman Act.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1725234	⤷ Start Trial	CA 2014 00002	Denmark	⤷ Start Trial
European Patent Office	1725234	⤷ Start Trial	C300634	Netherlands	⤷ Start Trial
European Patent Office	1725234	⤷ Start Trial	PA2014001	Lithuania	⤷ Start Trial
European Patent Office	1725234	⤷ Start Trial	C20140001 00107	Estonia	⤷ Start Trial
European Patent Office	1725234	⤷ Start Trial	14C0003	France	⤷ Start Trial
European Patent Office	1725234	⤷ Start Trial	1490006-2	Sweden	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 8,618,135